Sofgen Pharma S.A.
PROCF
Get informed when a big investor buys or sells
+ FollowMarket Cap$102.08M
Close$
Share Statistics
| Market cap | $102.08 Million |
|---|---|
| Enterprise Value | $402.32 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 132.54% |
|---|---|
| Return on Assets | 10.47% |
| Return on Invested Capital | 31.10% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.97 |
| Enterprise Value to EBIT | 4.38 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.79 |
| Debt to Equity | 8.07 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Procaps Group S.A
4,498 employees
CEO: Ruben Minski Procaps Group S.A. is a global pharmaceutical company engaged in the development, manufacturing, and commercialization of a diverse range of medical solutions. The company's portfolio encompasses branded prescription drugs, addressing nu...